Floatz logo

Acoramidis

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BayerSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) cohort.

Asset / SponsorPhaseRating
Eplontersen
AstraZeneca
Phase 2CCC

Same molecule, other indications

Acoramidis is also rated in:

amyloidosisDormant
BBB
Indicative ·
78 / 100
View asset →
Amyloid Cardiomyopathy, Transthyretin-RelatedDormant
BB
Indicative ·
66 / 100
View asset →
amyloidosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →